Johnson & Johnson Q4 results are in

Johnson & Johnson (JNJ) reported its Q4 earnings before the opening bell on Wall Street on Tuesday. Let’s take a closer look at how the pharmaceutical giant performed in the previous quarter.

The company reported total revenue of $24.804 billion in Q4 (up by 10.4% from the same period in 2020), below analyst forecast of $25.276 billion.

Earnings per share at $2.13 a share in the previous quarter (up by 14.5%, pretty much in line with analyst forecast of $2.12 a share.

Joaquin Duato, Chief Executive Officer commented on the Q4 and 2021 results: ”Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honoured to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers.”

”Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond,” Duato added.

Johnson & Johnson chart (Monthly)

Share price trading higher following the latest results, up by around 2% during the trading day on Tuesday at $166.66 per share.

Johnson & Johnson is the 12^th largest company in the world and with a total market cap of $438.19 billion.

You can trade Johnson & Johnson (JNJ) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD.

Sources: Johnson & Johnson, TradingView, GO Markets MT5, CompaniesMarketCap